Once-a-day HAART: Dream or reality?

HIV Clinical Trials

Volumn 4, Issue 3, 2003, Pages 193-201

  Maggiolo, Franco ^a   Ripamonti, Diego ^a   Suter, Fredy ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Adherence; Efficacy; Once a day HAART

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; CLINICAL STUDY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FEASIBILITY STUDY; HEALTH CARE NEED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LIFESTYLE; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE;

EID: 0038000376     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/1GER-1QJG-WDXM-489U     Document Type: Review

References (53)

1. Lucas GN, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
2. Deeks SG, Hecht FM, Swanson M, et al. HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43.
3. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. In: Program and abstracts of the 8th CROI; February 2001; Chicago, IL. Abstract 528.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
5. Ostrow D, Fox K, Kleenberger C, et al. Psychosocial correlates of incomplete adherence to HIV antiretroviral therapy (HAART): mental health matters. In: Program and abstracts of the 8th CROI; February 2001; Chicago, IL. Abstract 484.
6. Gordillo V, del Arno J, Soriano V, Gonzalez-Lahov J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
7. Stone VE, Adelson-Mitty J, Arnstern JH, Davenny K, Schoenbaum EE. What strategies do providers use to enhance adherence to HAART? In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract ThPeB5027.
8. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13:586-593.
9. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
10. Jordan J, Rosenzweig J, Athnak D, et al. Perceived influence of regimen characteristics on adherence. In: Program and abstracts of the 5th International Congress on Drug Therapy in HIV Infection; October 2000; Glasgow, Scotland. Abstract 121.
11. Bass D, Smith M. HIV patients prefer once-daily regimens. In: Program and abstracts of the 14th International Conference on AIDS; July 2002; Barcelona, Spain. Abstract MoPeB3290.
12. Papatheofanis FJ, Mukherjee J, Tuomari AV, Jackson S. HIV patients prefer once-daily dosing of antiretroviral medication. In: Program and abstracts of the 14th International Conference on AIDS; July 2002; Barcelona, Spain. Abstract MoPeB3287.
13. Moyle G. The APPT-1 study: assessing patients' preferred treatments. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection; October 2002; Glasgow, Scotland. Abstract 99.
14. Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C, and the AI454-143 Team. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AIDS. 1999;13:F87-F93.
15. Moore KHP, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239-2250.
16. Baril JG, Pollard RB, Raffi F, et al. Stavudine extended/prolonged release (XR/PRC) versus stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. In: Program and abstracts of the 14th International Conference on AIDS; July 2002; Barcelona, Spain. Abstract LBPeB9014.
17. Bowonwatanuwong C, Mootsikapun P, Supparatpinyo K, et al. A randomized, open label study to investigate abacavir and lamivudine as once daily components of a triple combination regimen. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argentina. Abstract 4.
18. Kearney BP, Flaherty JF, Sayre JR, et al. Effect of formulations and food on the pharmacokinetics of tenofovir DF. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy; April 2001; Noordwijk, the Nederlands. Abstract 3, 18.
19. Pozniak A, Staszewski S, Gallant J, et al. Comparison of the efficacy and safety of tenofovir disoproxil fumarete (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART) after 48 weeks of treatment. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection; October 2002; Glasgow, Scotland. Abstract P1.
20. Kearney BP, Flaherty JF, Wolf J, et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation. In: Program and abstracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 172.
21. Kearney BP, Isaacson E, Sayre J, Namini H, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. In: Program and abstracts of the 10th CROI; February 2003; Boston, MA. Abstract 533.
22. Zeier M, Sanne I, Van Der Berg M, Quinn J, Shaw A. Efficacy and safety of emtricitabine (FTC) triple combination therapy in HIV-1 infected treatment-naive male and female patients. In: Program and abstracts of the 41st ICAAC; December 2001; Chicago, IL. Abstract I-1933.
23. Joshi AS, Barrett JS, Fiske WD, et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. In: Program and abstracts of the 39th ICAAC; September 1999; San Francisco, CA. Abstract 1201.
24. Van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77-F82.
25. Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. AIDS. 2000, 14:2485-2494.
26. Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults. Antiviral Ther. 2000;5:267-272.
27. Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen. 48-week results. In: Program and abstracts of the 39th ICAAC; September 1999; San Francisco, CA. Abstract LB2.
28. Van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the 10th CROI; February 2003; Boston, MA. Abstract 176.
29. Kurowski M, Staszewski S, Arslan A, et al. Influence of 50 mg, 100 mg and 200 mg ritonavir (RTV) on the pharmacokinetics (PK) of amprenavir (APV) after multiple doses in healthy volunteers for once daily (QD) and twice daily (BID) regimens. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argentina. Abstract 351.
30. Arasteh K, Wood R, Teofilo E, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART naive HIV-1 infected adults over 24 weeks (APV20001). In: Program and abstracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 218.
31. Maggiolo F, Rizzi M, Finazzi G, Suter F. Once-a-day indinavir therapy in virologically controlled HIV+ persons. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract TuPpA1155.
32. Suleiman J, Rhodes R, Campo R, et al. Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen. In: Program and abstracts of the 8th CROI; February 2001; Chicago, IL. Abstract 336.
33. Montaner JSG, Saag M, Schwartz R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel (SQV) in HIV infected anti-retroviral naive patients. In: Program and abstracts of the Frontiers in Drug Development for Antiretroviral Therapies; December 2000; San Juan, Puerto Rico. Abstract 48.
34. Hsyu PH, Lewis R, Tran J, et al. Pharmacokinetics (PK) of nelfinavir (NFV) after once-daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract LbPeB7049.
35. Cardiello P, Van Heeswijk R, Monhaphol T, et al. HIV-NAT 001.3: the safety, efficacy and pharmacokinetics (PK) of 1600 mg saquinavir (soft gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV, 100 mg) in a once-daily (qd) dosing regimen in HIV-infected Thai patients. In: Program and abstracts of the 1st IAS; July 2001; Buenos Aires, Argentina. Abstract 59.
36. Eron J, Bernstein B, King M, et al. Once-daily versus twice daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48 week follow-up. In: Program and abstracts of the 9th CROI; February 2002; Seattle, WA. Abstract 409.
37. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD vs efavirenz (EFV) QD with fixed-dose ZDV + 3TC BID: comparison of antiviral efficacy and safety. In: Program and abstracts of the 42nd ICAAC; September 2002; San Diego, CA. Abstract 1076.
38. Schuermann D, Gathe J, Sanne I, Wood R, on behalf of the SOLO study team. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO study. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection; October 2002; Glasgow, Scotland. Abstract PL 14.4.
39. Staszewski S, Haberl A, Gute P, et al. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antiviral Ther. 1998;3(suppl 4):55-56.
40. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Ther. 2001;6:249-253.
41. Landman R, Thiam S, Canestri A, et al. Long term evaluation (15 months) of ddl, 3TC and efavirenz once daily regimen in naive patients in Senegal: ANRS 12-04/IMEA 011 study. In: Program and abstracts of the 9th CROI; February 2002; Seattle, WA. Abstract 458.
42. Molina JM, Ferchal F, Jounot V, et al. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults: 96-week follow-up of the ANRS 091 trial. In: Program and abstracts of the 8th ECCATHI; October 2001; Athens, Greece. Abstract 221.
43. Jordan W, Jefferson R, Yemofio F, et al. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddl): a very simple, safe, and effective once-daily regimen. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract TuPeB3207.
44. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr. 2001;27:260-265.
45. Hsieh SM, Hung CC, Lu PL, Chen MY, Chang SC. Preliminary experience of adverse drug reactions, tolerability and efficacy of a once-daily regimen of antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2000;24:287-288.
46. Skowron G, Kuritzkes DR, Thompson MA, et al. Once-daily quadruple drug therapy with adefovir dipivoxil, lamivudine, didanosine and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002;186:1028-1033.
47. Maggiolo F, Arici C, Gregis G, et al. A controlled, randomized, prospective study on a once-a-day therapy for HIV infection. In: Program and abstracts of the 42nd ICAAC; September 2002; San Diego, CA. Abstract H-163.
48. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
49. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;5:371-378.
50. Fauci AS, Bartlett JG, Goosby EP, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998; 47 (N° rr-5). Updated as a living document on February 4, 2002. Available from the HIV/AIDS treatment information service, www.hivatis.org
51. Conway B, Prasad J, Smith N, de Vlaming S. Once-daily vs. twice-daily directly observed (DOT) for management of HIV-infected individuals in a methadone program. In: Program and abstracts of the 41st ICAAC; December 2001; Chicago, IL. Abstract 1917.
52. Dybul M, Yoder C, Belson M, et al. Short cycle intermittent HAART: a pilot study. In: Program and abstracts of the 13th International Conference on AIDS; July 2000; Durban, South Africa. Abstract LbOr12.
53. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002:16(suppl 1):S5-S37.